EDIT vs NKTX
EDIT: A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL receptor upregulation. NKTX: Nkarta is a clinical-stage biotech developing off-the-shelf, engineered natural killer (NK) cell therapies aimed at treating autoimmune diseases through targeted B-cell depletion.
Side-by-side fundamentals
| Metric | EDIT | NKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.78 | $2.41 | |
| Market cap as of 2026-07-23 | $421M | $172M | |
| Net margin as of 2026-07-23 | -281.6% | -17566.7% | EDIT higher |
| Operating margin as of 2026-07-23 | -281.3% | -19250.0% | EDIT higher |
| ROE as of 2026-07-23 | -677.4% | -30.9% | NKTX higher |
| ROA as of 2026-07-23 | -58.3% | -24.2% | NKTX higher |
| Debt / equity as of 2026-07-23 | 12.40 | 0.00 | NKTX lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +27.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 2.08 | 0.92 | |
| 1-year return as of 2026-07-22 close | -8.3% | +34.4% | NKTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.